U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Pivmecillinam – Oral Products
  1. Development Resources

Pivmecillinam – Oral Products

 

Minimum Inhibitory
Concentrations (mcg/mL)

Disk Diffusiona
(zone diameters in mm)

Pathogenb

S

I

R

S

I

R

Enterobacteralesc

M100 standard is recognized

S = susceptible; I = intermediate; R = resistant
a For disk diffusion, use paper disks impregnated with 10 mcg mecillinam.
b Susceptibility interpretive criteria are based on a dose of 185 mg pivmecillinam orally three times a day.
c Clinical efficacy was shown for Escherichia coli and Proteus mirabilis in patients with uncomplicated urinary tract infections.

Back to Top